Ensysce Biosciences (ENSCW) Change in Accured Expenses (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Change in Accured Expenses of $3161.0 for Q3 2025, down 98.46% year-over-year from $205252.0 in Q3 2024, and up 100.83% quarter-over-quarter from -$382691.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Change in Accured Expenses (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Change in Accured Expenses data on file, last reported at $3161.0 in Q3 2025.
- Change in Accured Expenses for Q3 2025 came in at $3161.0, down 98.46% year-over-year; the trailing twelve-month figure through Sep 2025 was $20020.0 (down 98.21% YoY), and the FY2024 annual result was $43927.0, up 135.56% from the prior year.
- Change in Accured Expenses improved to $3161.0 in Q3 2025 per ENSCW's latest filing, from -$382691.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.6 million in Q3 2021 and troughed at -$987997.0 in Q2 2023.
- A 5-year average of $121582.8 and a median of $3161.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses jumped 1708.58% in 2022, then plunged 1610.14% in 2023.
- A 5-year view of Change in Accured Expenses shows it stood at -$323228.0 in 2021, then plunged by 181.8% to -$910856.0 in 2022, then surged by 219.08% to $1.1 million in 2023, then plunged by 99.01% to $10752.0 in 2024, then sank by 70.6% to $3161.0 in 2025.
- Business Quant data shows ENSCW's Change in Accured Expenses at $3161.0 in Q3 2025, -$382691.0 in Q2 2025, and $388798.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3,161.00 |
| Sep 30, 2025 | 3,161.00 |
| Jun 30, 2025 | -382,691.00 |
| Jun 30, 2025 | -382,691.00 |
| Mar 31, 2025 | 388,798.00 |
| Mar 31, 2025 | 388,798.00 |
| Dec 31, 2024 | 10,752.00 |
| Dec 31, 2024 | 10,752.00 |
| Sep 30, 2024 | 205,252.00 |
| Sep 30, 2024 | 205,252.00 |
| Jun 30, 2024 | -199,360.00 |
| Jun 30, 2024 | -199,360.00 |
| Mar 31, 2024 | 27,283.00 |
| Mar 31, 2024 | 27,283.00 |
| Dec 31, 2023 | 1.08 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | -25,370.00 |
| Sep 30, 2023 | -25,370.00 |
| Jun 30, 2023 | -987,997.00 |
| Jun 30, 2023 | -987,997.00 |